Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
about
Chronic Lyme disease: a reviewEucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycinEffects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferiAn in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazoleA proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treatedIneffectiveness of tigecycline against persistent Borrelia burgdorferiManagement of Lyme arthritis.In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapyPenetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Chronic Lyme disease: the controversies and the science.Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.Review of treatment options for lyme borreliosis.Lyme neuroborreliosis-epidemiology, diagnosis and management.Treatment of tick-borne diseases.Lyme disease: the next decade.Lyme disease: a growing threat to urban populationsLyme disease in paediatricsEfficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic review.Neuroborreliosis: the Guillain-Barré mimickerPassage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.Long-term Follow-up of Patients With Lyme Disease: Longitudinal Analysis of Clinical and Quality-of-life Measures.Use of third-generation cephalosporins. Spirochetes.Controversies in Persistent (Chronic) Lyme Disease.Antibiotics for the neurological complications of Lyme disease.Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis.In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.Efficacy of antibiotic prophylaxis for prevention of Lyme disease.Lyme neuroborreliosis in children.Follow-up of patients treated with oral doxycycline for Lyme neuroborreliosis.Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America.The Financial Implications of a Well-Hidden and Ignored Chronic Lyme Disease Pandemic.Therapy of Lyme borreliosis in children.Lyme disease: clinical diagnosis and treatment.
P2860
Q22252200-7F394FD0-DC71-48F9-9F4A-9BE57798CC52Q24675848-482C7E5C-AECC-4C08-9FBA-73AEBB36E6BEQ24677545-C23191E7-4E89-4224-8D96-0FCB96D7B4F8Q28137907-B5DC1F0B-BA54-46FC-8F56-A990E45F0ABDQ28292075-9AACC4EC-D458-42E7-9E7A-0970D141A15EQ33613691-82E7017E-1E9C-4554-AA31-B28B4131D302Q33647324-059BEE17-A99E-4812-A09B-0F6D1C998ADFQ33722062-C91FE88B-7EC7-4872-B24E-466F9E882208Q34142328-500EF574-A63D-4C4D-ACD1-0955AF8CC086Q34205531-ABE13B00-D177-45AF-BF6E-D8A7D72CF513Q34336214-3BD75C69-9054-43C4-97F8-A15832A23019Q34471224-E5F2B973-A37E-41C3-9D1D-B5B7539C4BD2Q34487119-9514FD69-0702-40BF-BA10-085C3EDBDC19Q34874402-C8D91761-463E-4C16-BFA4-715877C46C7FQ35026635-CAA65D61-09D6-4005-A3C6-DAF561D23AF1Q35110893-BE3214D0-5AD5-427F-ADA4-7C4C1DE452E4Q35627026-294CD6D3-44C9-4B39-B8AD-5CD9FF0583FAQ35658597-BF1CAE26-C89D-4F2A-8EAC-70E1CD4F3919Q35808450-A94172FC-25B0-4F75-BF36-543618A7587EQ35817227-79AE58ED-AA25-4BF4-BE99-0B554446C22CQ36679488-94354C94-A1B9-4A68-9A69-BDCF56AB01E4Q36948131-A54ABA49-75E4-46BE-A8F0-728361580C72Q37381384-369E4FBF-A337-4803-A269-980EA3FF36E2Q37403994-DB91F7FF-83C4-43AF-8361-319F311668EEQ39032987-6A793F2F-4274-41E0-A93F-1F2294B2CA02Q39781985-7AD2E568-C7E4-4C7A-B1D7-7AF91EC25E57Q40674670-088A13FA-B8B7-4DB7-92D5-CFD28DE4A9B7Q41109026-BEFB9CBB-4D6E-41F1-8FD3-6F46D4A31872Q41114759-62699211-A4DC-4F7F-9465-AA521C28A523Q43451624-6D6AD39D-B6F2-4587-AD6A-5BDFB2A7AF49Q44628961-18748733-CBA7-4205-9C92-391716AF605BQ50041916-38557DAB-39C4-460C-B221-9397B67958B2Q53990849-37579321-FF56-4DF0-A37C-33C967DED7E9Q55284263-98B92760-B2D1-477A-A6FD-99E2D4248A70
P2860
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
description
1991 nî lūn-bûn
@nan
1991 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
name
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@ast
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@en
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@nl
type
label
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@ast
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@en
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@nl
prefLabel
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@ast
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@en
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@nl
P2093
P356
P1476
Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.
@en
P2093
Einhäupl KM
Pfister HW
Preac-Mursic V
Schielke E
P304
P356
10.1093/INFDIS/163.2.311
P407
P577
1991-02-01T00:00:00Z